Interim CSO / Scientific Advisor

Graham Pockley is the CEO of multimmune GmbH, Munich, Emeritus Professor of Immunobiology and Chief Scientific Officer (interim) of Alphageneron Pharmaceuticals Inc. USA. He is also the former Director of the John van Geest Cancer Research Centre at Nottingham Trent University, UK, and was the Founder and CEO of the flow cytometry resource Chromocyte, the assets of which have now been sold to Biocompare.

Graham’s e3xtensive academic career has focused on the immunobiology of disease, the development of new immunotherapeutic strategies for treating aggressive and ‘orphan’ cancers, new approaches for analysing and interpreting complex datasets and defining new biomarkers of disease presence, status and response to therapy in patients with cancer.

multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists’ (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. This makes this form of Hsp70 an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics (‘theranostics’).

Graham holds a BSc (Hons) in Biochemistry from the University of Sheffield, UK and a PhD in Immunology from Sheffield Hallam University, also in Sheffield, UK.